Hip-Fracture Surgery on Patients in Clopidogrel Therapy
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 356
- 主要终点
- Surgical Blood Loss
研究概览
简要总结
Patients in Clopidogrel therapy alone or in combination with acetylsalicylic acid (Dual Antiplatelet Therapy (DAPT) presenting with a hip-fracture represent the surgeon with the dilemma of putting the patient at risk of a major blood loss during and after surgery, or putting the patient at risk of a thromboembolic event after surgery. The investigators hypothesize that the risk of a major blood loss in patients that are still under the effect of Clopidogrel or DAPT during or after hip-fracture surgery is relatively low. The investigators have conducted a retrospective observational study on hip-fracture patients to test this hypothesis.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All patients operated with short intramedullary nail for hip-fractures, in the study period. (1st of Jan. 2011-31st of Dec. 2013)
排除标准
- •patients operated >24 hours after admission, patients in other forms of anticoagulation medication except acetylsalicylic acid (including vitamin K antagonists, dipyridamole, dabigatran, apixaban and rivaroxaban), missing data on blood loss in patient chart, missing blood samples in the first 4 days and extra-national patients (follow up not possible). Patients operated on both sides during the inclusion period were only included with data on their latest operation.
研究组 & 干预措施
Clopidogrel
Patients in Clopidogrel or Dual Antiplatelet Therapy (Clopidogrel+Acetylsalicylic acid) at the time of admission AND who are operated <24 hours after admission.
干预措施: Clopidogrel (Drug)
结局指标
主要结局
Surgical Blood Loss
时间窗: at time of surgery
Blood loss as assessed by the surgeon
次要结局
- Number of transfusions(From admission to third day after surgery)
- Massive transfusion(within 24 hours of surgery)
- 30 and 90 day mortality(30 and 90 days postoperatively)
- Total BLood Loss(From admission to third day after surgery.)
研究者
Peter Toft Tengberg
Consultant
Hvidovre University Hospital